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AbstrAct
Objective
To assess the accuracy of the AbC-19 Rapid Test lateral 
flow immunoassay for the detection of previous severe 







2847 key workers (healthcare staff, fire and rescue 
officers, and police officers) in England in June 2020 
(268 with a previous polymerase chain reaction (PCR) 
positive result (median 63 days previously), 2579 with 
unknown previous infection status); and 1995 pre-
pandemic blood donors.
Main OutcOMe Measures
AbC-19 sensitivity and specificity, estimated using 
known negative (pre-pandemic) and known positive 
(PCR confirmed) samples as reference standards 
and secondly using the Roche Elecsys anti-
nucleoprotein assay, a highly sensitive laboratory 
immunoassay, as a reference standard in samples 
from key workers.
results
Test result bands were often weak, with positive/
negative discordance by three trained laboratory staff 
for 3.9% of devices. Using consensus readings, for 
known positive and negative samples sensitivity was 
92.5% (95% confidence interval 88.8% to 95.1%) 
and specificity was 97.9% (97.2% to 98.4%). Using 
an immunoassay reference standard, sensitivity was 
94.2% (90.7% to 96.5%) among PCR confirmed cases 
but 84.7% (80.6% to 88.1%) among other people with 
antibodies. This is consistent with AbC-19 being more 
sensitive when antibody concentrations are higher, 
as people with PCR confirmation tended to have 
more severe disease whereas only 62% (218/354) 
of seropositive participants had had symptoms. If 1 
million key workers were tested with AbC-19 and 10% 
had actually been previously infected, 84 700 true 
positive and 18 900 false positive results would be 
projected. The probability that a positive result was 
correct would be 81.7% (76.8% to 85.8%).
cOnclusiOns
AbC-19 sensitivity was lower among unselected 
populations than among PCR confirmed cases of 
SARS-CoV-2, highlighting the scope for overestimation 
of assay performance in studies involving only PCR 
confirmed cases, owing to “spectrum bias.” Assuming 
that 10% of the tested population have had SARS-
CoV-2 infection, around one in five key workers testing 




After infection with severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), most, but not all, infected 
people generate antibodies against the viral spike (S) 
or nucleoprotein (N) antigen.1 2 Several lateral flow 
immunoassays (LFIAs)—small, pregnancy test format 
devices that can deliver testing rapidly and at scale—
have recently become available that detect antibodies 
against SARS-CoV-2 proteins. These devices have two 
potential main uses: population serosurveillance and 
assessment of individual risk of developing immunity 
to coronavirus disease 2019 (covid-19).3-5 The US Food 
and Drug Administration recently (24 September 2020) 
licensed an LFIA for office use (that is, in supervised 
environments), on the basis that it may predict 
immunity (https://www.fda.gov/media/139789/
download); if this is validated, then it could result in 
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WhAt Is AlreAdy knoWn on thIs topIc
A previous study reported 97.7% sensitivity and 100% specificity of the AbC-19 
Rapid Test to detect SARS-CoV-2 antibodies
However, these findings may be optimistic because the study excluded 
participants with unclear antibody status according to laboratory based 
immunoassays
Most studies evaluating accuracy of SARS-CoV-2 antibody tests have used a “two 
gate” or “diagnostic case-control” design, but the effect of spectrum bias on 
estimates of test sensitivity is unclear
WhAt thIs study Adds
Using pre-pandemic samples, the specificity of AbC-19 was 97.9% (97.2% to 
98.4%), implying that, at 10% prevalence of previous infection, around one in 
five positive results would be incorrect
Evidence of spectrum bias existed, with ~10% higher sensitivity (absolute 
difference) in key workers with polymerase chain reaction confirmed infection, 
suggesting that two gate studies may overestimate sensitivity
Trained laboratory staff reported that test bands were often weak and disagreed 
on device positivity for 3.9% of tests, so accuracy may be lower if used by 
members of the public
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widespread use of this class of devices. However, this 
application is also critically dependent on high test 
accuracy: if assay specificity is not sufficiently high, 
false positive results could result in non-immune 
people being assigned to high SARS-CoV-2 exposure 
environments.6 7
Evaluations of different LFIAs for SARS-CoV-2 have 
produced widely varying estimates of accuracy.2  8 
In some jurisdictions, large numbers of devices 
are available, with varying levels of performance 
characterisation.9 In a recent Cochrane review,2 most 
LFIA evaluations were considered to be at high risk 
of bias, owing to use of a “two gate” (also known as 
“diagnostic case-control”) design.10 These studies 
evaluate LFIAs on a set of pre-pandemic blood samples 
and on a separate set of convalescent samples taken 
from cases of SARS-CoV-2 confirmed by polymerase 
chain reaction (PCR). This study design has been 
associated with overestimation of test accuracy on 
average across multiple clinical settings,10 11 referred 
to as “spectrum bias.”12 The sensitivity of SARS-CoV-2 
antibody tests based on PCR confirmed cases could 
be overestimated if people with more severe disease 
are more likely to have been PCR tested than those 
with milder illness, and if, as is known to occur,13-15 
people with more severe illness produce higher 
antibody concentrations. This tendency would make 
confirmed cases easier to diagnose than cases in other 
people who, although previously infected, were not 
PCR tested. Despite the importance of obtaining real 
world estimates of test accuracy, however, potential 
spectrum bias has not been assessed to date in SARS-
CoV-2 antibody testing. This is partly due to the need 
for larger sample sizes in the alternative approach of 
assessing test accuracy directly in a target cohort (a so-
called “one gate” design) and partly due to the lack of 
a true gold standard test to assess previous infection in 
such a cohort.
This study helps to reduce uncertainties in the 
evaluation of a new SARS-CoV-2 rapid antibody test, the 
“AbC-19 Rapid Test” (AbC-19 hereafter). Produced by the 
UK Rapid Test Consortium (UK-RTC), the test contains 
trimeric SARS-CoV-2 S protein attached to a membrane, 
which, when recognised by IgG antibodies, results in 
formation of a band visible to the user. Professional use 
CE marking has been obtained by self-certification. The 
PANDEMIC study from Ulster University, which is not yet 
peer reviewed, reports sensitivity of 97.7% (n=304; 95% 
confidence interval 95.7% to 99.3%) and specificity 
of 100% (n=350; 95% confidence interval reported as 
100% to 100%) to detect presence of antibodies.16 This 
suggests that the AbC-19 test gives no false positive 
results. However, these may be overestimates of test 
accuracy, as blood samples from a number of people 
were excluded from this test evaluation on the basis of 
results of other tests (pre-selection). We evaluated AbC-
19 in the detection of previous infection with SARS-
CoV-2 by using venous blood samples collected from UK 
key workers in the EDSAB-HOME (Evaluating Detection 
of SARS-CoV-2 AntiBodies at HOME) study15 and pre-
pandemic samples from blood donors.
Methods
study participants
In total, across the two parts of the study, we analysed 
blood samples from 4842 people: 2847 people 
recruited through the EDSAB-HOME study,15 and 
an additional 1995 pre-pandemic samples from the 
COMPARE blood donor study. Each sample was from a 
separate individual.
eDsab-HOMe study: recruitment
EDSAB-HOME is a study of key workers in the UK 
(ISRCTN 56609224).15 People were eligible to enrol 
in the study if they were currently working at their 
place of work, aged 18 years or over, and able to read 
English and had an in-use personal email address and 
mobile phone number. Anyone who was currently 
experiencing covid-19 compatible symptoms, had 
experienced any such symptoms in the previous seven 
days, met the government’s criteria for “exceptionally 
vulnerable,” was unable to read normal sized print, 
or was taking part in any covid-19 vaccine trials was 
not eligible for enrolment. Symptom history was not 
part of the eligibility criteria. All data and samples 
were collected in June 2020 and form a convenience 
sample. The purpose of the study was to assess the 
accuracy of LFIAs suitable for deployment at scale in 
key workers in the UK. All participants completed an 
online questionnaire, which included information on 
any previous tests they had had for SARS-CoV-2, their 
beliefs about whether they had had covid-19, and 
any signs and symptoms that they or their household 
members had experienced since 1 January 2020. On the 
basis of this information, we categorised participants 
by using a version of the World Health Organization’s 
criteria for confirmed, suspected, and probable cases, 
adapted to the UK context and taking into account 
the confirmation of community transmission on 5 
March 2020 (supplementary material, table S1).15 
Previous PCR status was self-reported and validated 
by comparison with national laboratory records after 
recruitment. Recruitment into the study was through 
three streams: fire and police officers (stream A), 
healthcare workers who were recruited without any 
restrictions on previous PCR status (stream B), and 
healthcare workers recruited only if they had a history 
of SARS-CoV-2 PCR positivity (stream C) (fig 1). On 
attending a study clinic, each participant had a venous 
blood sample taken, which was anticoagulated using 
EDTA. In participants with previous PCR positivity, 
onset of illness occurred a median of 63 (interquartile 
range 52-75) days before the clinic visit. Plasma was 
separated by centrifugation and stored at −80°C until 
use. No samples were frozen and thawed more than five 
times. Demographic details are in the supplementary 
materials (table S2), as is additional information on 
the relation between PCR testing and symptoms.
cOMPare study
We used stratification by age, sex, and region to 
randomly select 2000 participants as “known 
negative” samples from among a pool of almost 29 029 
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participants recruited into the COMPARE study, a pre-
pandemic (2016-17) blood donor cohort in England 
(ISRCTN 90871183). Of these participants, 1995 had 
samples available for analysis (fig 1). The selection 
strategy aimed to maximise national geographical 
representativeness of the sample, with approximately 
equal numbers of people across participating age 
groups (18-70 years). Demographic details are in the 
supplementary materials (table S3).
approach 1: Pcr positive cases and pre-pandemic 
samples as reference standard
We used two approaches to estimate the accuracy of 
AbC-19, both pre-specified (fig 1). In approach 1, we 
estimated the sensitivity and specificity of AbC-19 
by using two sets of samples with known previous 
infection status: pre-pandemic samples (“known 
negatives”) from the COMPARE study (n=1995) and 
samples collected from participants in EDSAB-HOME 
who self-reported having had a previous PCR positive 
test for SARS-CoV-2 (“known positives”) (n=268).
approach 2: laboratory immunoassays as reference 
standard
When the EDSAB-HOME protocol was written, large 
scale development and evaluation of SARS-CoV-2 
immunoassays was an emerging field. We pre-
specified the use of a laboratory reference standard 
indicative of previous SARS-CoV-2 infection as a single 
assay with the highest published accuracy available 
to us after sample collection; as anticipated in the 
protocol, this was the Roche Elecsys assay, which 
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Fig 1 | Flow diagram of recruitment and analysis. Pcr=polymerase chain reaction
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measures antibodies against the N protein.17 We also 
analysed all samples with the EUROIMMUN anti-S IgG 
immunoassay, which detects antibodies against the S 
protein S1 domain, one domain present in the AbC-19 
test antigen. We repeated immunoassays that failed for 
technical reasons, in accordance with usual clinical 
practice, and excluded samples with insufficient 
volume for testing from analyses. Although the primary 
reference standard used here is the Roche Elecsys 
immunoassay (threshold 1.0), having previously 
noted the strong positive correlation between Roche 
Elecsys and EUROIMMUN assay results (ρ=0.9315), 
in sensitivity analyses we also used a EUROIMMUN 
immunoassay (threshold 0.8, as described15) and a 
composite reference standard defined as positive on 
either Roche Elecsys or EUROIMMUN versus negative 
on both. We made these comparisons separately for the 
known positive (n=268) and all other EDSAB-HOME 
samples (n=2579), to assess for potential spectrum 
bias associated with estimating test sensitivity from 
PCR confirmed cases relative to other people with 
evidence of previous infection. We refer to the latter 
sample set (n=2579) as samples from people with 
unknown previous infection status. We analysed 
samples from 2847 EDSAB-HOME study participants 
(fig 1), a group comprised of police, fire, and healthcare 
staff who are of working age and worked throughout 
lockdown.15
laboratory protocol
Test evaluation (product FG-FD51919, lot A2007003) 
was performed in an accredited WHO Pre-Qualification 
Evaluating Laboratory based in PHE Colindale, London, 
by experienced laboratory staff following training 
by the manufacturer. Trained staff dropped 2.5 μL of 
plasma into the lateral flow device followed by 100 
μL of chase buffer; devices give a qualitative (positive 
or negative) result for presence of IgG antibodies 
and include a control band. A result was considered 
positive if two bands were present and negative if 
only the control band was present. Devices in which 
a control band did not develop were considered to 
have given invalid results (n=5) and were repeated. 
Three readers independently read each device using 
the WHO scoring system for subjectively read assays 
(0=negative; 1=very weak, but definitely reactive; 
2=medium to strong reactivity).18 For assessment 
of test sensitivity and specificity, and in measuring 
discordance in AbC-19 positivity across the multiple 
readers, scores of 1 and 2 were grouped together as 
“positive.” If the three independent readers disagreed 
on the positivity of a sample, the majority reading was 
taken as the “overall” or consensus test result in our 
primary analysis, as per the WHO protocol.18
None of the staff who ran the laboratory immuno-
assays had access to any clinical information on the 
samples, and laboratory immunoassays were all 
completed before any testing of the index test. For all 
EDSAB-HOME samples and the first 350 pre-pandemic 
samples analysed, readers were blind to the reference 
standard (including randomising order of known 
positives and negatives), as well as to any information 
on study participants or results on other assays. The 
additional 1650 pre-pandemic samples were analysed 
after the other samples, for which complete blinding 
was difficult. We retested known negative samples if 
they tested positive on the AbC-19 device. For all other 
samples, we retested if the result was different from 
the composite reference standard defined above. Our 
primary results are those based on the initial set of 
readings for each sample. Results following retesting 
are reported as secondary, as only discordant samples 
were retested, which does not reflect how the test 
would be used in the real world. More details are in the 
supplementary materials.
statistical analysis
We estimated 95% confidence intervals around pro-
portions by using Wilson’s method in R 3.5.1. In 
approach 1, we estimated AbC-19 test sensitivity and 
specificity as the proportion of known positive samples 
that tested positive and the proportion of known 
negative samples that tested negative, respectively. 
Estimates of sensitivity are also presented by days 
since onset of symptoms and separately for people 
who reported no symptoms. Test specificity estimates 
are further reported by age group.
In approach 2, AbC-19 test sensitivity and specificity 
are reported for each of the immunoassay reference 
standards described above. AbC-19 test results are also 
stratified by adapted WHO categorisation. To facilitate 
evaluation of potential spectrum bias associated 
with estimating test sensitivity from PCR confirmed 
cases, we stratified approach 2 estimates by whether 
participants were known to have had PCR confirmed 
SARS-CoV-2 infection (known positive sample set: 
n=268) or whether their previous infection status was 
unknown before antibody testing (n=2579). However, 
to reflect the “one gate” nature of EDSAB-HOME 
streams A and B, we also report as a secondary analysis 
results from all stream A and B participants, regardless 
of previous PCR positivity (n=2693).
Additional post hoc analyses assessed the 
association between age, sex, and ethnicity and 
specificity, using multivariable logistic regression; 
anti-S1 antibody indexes (EUROIMMUN) and AbC-19 
test sensitivity; and the level of disagreement between 
three independent reviewers. These analyses are 
described in the supplementary materials.
sample size calculations
Study size was based on sample size calculations done 
as part of the EDSAB-HOME research protocol (see 
supplementary materials).
Positive and negative predictive values
We calculated positive and negative predictive values 
for prevalence of previous infection of 5%, 10%, 15%, 
20%, and 25% as functions of estimated sensitivity and 
specificity. We calculated 95% confidence intervals by 
using a simulations based approach in R, accounting 
for the sampling variation (uncertainty) in both 
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estimates. We used the estimates of specificity based 
on pre-pandemic sera (known negatives). We present 
two sets of estimates of positive predictive value 
and negative predictive value based on alternative 
estimates of test sensitivity: sensitivity based on 
analysis of PCR confirmed cases and sensitivity based 
on comparison with the primary (Roche) immunoassay 
reference standard in people with unknown previous 
infection status.
accounting for multiple readers
For each sample set (known positives, known 
negatives, and unknown previous infection status), 
we report numbers of disagreements between the 
three independent reviewers. In the presence of 
discordant results across readers, we anticipated that 
estimating test sensitivity and specificity based on the 
majority reading would lead to a slight upward bias 
in these estimates. To explore the potential extent of 
this, within approach 1 we did additional analyses in 
which each reading was treated as a separate “test.” 
We fitted multinomial distributions to tables of cross 
classified readings, assuming a log-linear model for 
underlying probabilities. Full details are available in 
the supplementary materials.
Patient and public involvement
As part of the EDSAB-HOME study design, patient and 
public involvement was provided by a public panel 
run through NIHR Birmingham Biomedical Research 
Centre and NIHR Applied Research Collaboration 
West Midlands. The panel commented on study 
design, acceptability, and strategies for effective 
recruitment. The questionnaire, communications with 
the participants, and all public facing documentation 
were informed and refined by this engagement. We 
did not seek public engagement in the design of the 
laboratory aspects of the study or in the interpretation 
of the results.
results
approach 1: sensitivity and specificity in “known 
positives” and “known negatives”
In 1995 pre-pandemic known negative samples 
from the COMPARE study, test specificity was 97.9% 
(95% confidence interval 97.2% to 98.4%) (table 
1). Specificity was slightly lower in women (96.9%, 
95.6% to 97.8%) than in men (98.9%, 98.0% to 
99.4%) (adjusted odds ratio favouring false positivity 
in women 2.9, 95% confidence interval 1.5 to 5.9). 
After retesting of discordant samples, a female excess 
was still evident (adjusted odds ratio 4.7, 1.4 to 17) 
(table S4).
Among 268 (9.4%) EDSAB-HOME participants 
who had had a positive PCR test for SARS-CoV-2, test 
sensitivity was 92.5% (88.8% to 95.1%) (table 2). In 
this group, the first positive PCR test had occurred a 
median of 59 days previously. Days since first positive 
test was 21 or more in 251/268 cases. Sensitivity was 
estimated to be substantially lower among the 12 
participants who reported no symptoms (sensitivity 
58.3%, 32.0% to 80.7%) than among the 256 who 
reported symptoms (sensitivity 94.1%, 90.6% to 
96.4%), and may decline slightly in PCR positive 
people with longer times between symptoms and 
blood sampling (table 2; figure S1).
False negative AbC-19 tests occurred predominantly 
in samples with lower EUROIMMUN anti-S indices (fig 
2, A; figure S1). Three participants (all asymptomatic) 
had clear negative results on both immunoassays in 
addition to the AbC-19 device.
approach 2: analysis of “unknown previous 
infection status” eDsab-HOMe study samples
In EDSAB-HOME participants with unknown previous 
infection status (all those who had not had a positive 
PCR test; fig 2, B), antibody indices from anti-N and 
anti-S assays were highly correlated (Spearman’s 
ρ=0.93; P<0.001). We observed clear delineation bet-
ween two main clusters of participants (with versus 
without antibodies), whereas the true previous infection 
status of a small minority of samples is less clear.
Among participants with unknown previous 
infection status testing positive on the Roche reference 
standard, 62% (218/354) reported symptoms 
compatible with covid-19 since 1 January 2020. 
The remaining 136 included 55 (16%) people who 
reported no compatible symptoms and 81 (23%) who 
“did not know” whether they had had any compatible 
symptoms.
Table 3 shows estimates of sensitivity and specificity 
of the AbC-19 test based on comparison with the three 
immunoassay reference standards, across all EDSAB-
HOME study participants. Among the unknown 
previous infection status samples, sensitivity was 
84.7% (80.6% to 88.1%) and specificity was 98.9% 
(98.4% to 99.3%) on the basis of the Roche reference 
standard (table 3). This was lower than sensitivity 
among the PCR confirmed cases, which was estimated 
as 94.2% (90.7% to 96.5%) on the basis of the same 
reference standard. In sensitivity analyses, we observed 
a similar pattern on the basis of the EUROIMMUN 
reference standard and a composite of the two assays 
(table 3). This is expected given the strong positive 
correlations between the immunoassay results studied 
(fig 2).
table 1 | approach 1: specificity of abc-19 rapid test estimated from 1995 pre-pandemic samples (“known negatives”)
result true negatives False positives total known negatives specificity, % (95% ci)
Primary result (result of first test*) 1953 42 1995 97.9 (97.2 to 98.4)
After re-testing of 42 false positives only 1979 16 1995 99.2 (98.7 to 99.5)
*2/1995 samples yielded invalid results (control band failed) on first test and were repeated; re-test value (both negative) was used for these as part of 
primary result.
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Retesting discordant samples did not substantially 
alter these estimates (table S4). Test accuracy estimates 
did not vary across recruitment stream A or B (tables 
S5 and S6). Based on comparison of test results in 
all EDSAB-HOME stream A and B samples with the 
Roche reference standard, regardless of previous PCR 
positivity (one gate estimate), AbC-19 test sensitivity 
was estimated as 86.6% (83.2% to 89.4%) (table S7).
table 2 | approach 1: sensitivity of abc-19 rapid test based on samples from 268 people with previous positive 
polymerase chain reaction test (“WHO confirmed” category: “known positives”)
time since symptom onset true positives False negatives total known positives sensitivity, % (95% ci)
All 248 20 268 92.5 (88.8 to 95.1)
Asymptomatic 7 5 12 58.3 (32.0 to 80.7)
All symptomatic 241 15 256 94.1 (90.6 to 96.4)
8-21 days 5 0 5 100 (56.6 to 100.0)
22-35 days 19 1 20 95.0 (76.4 to 99.7)
36-70 days 136 6 142 95.8 (91.1 to 98.0)
≥71 days 81 8 89 91.0 (83.3 to 95.4)
All after retests* 251 17 268 93.7 (90.1 to 96.0)










































































Fig 2 | relation between abc-19 test results and immunoassay indices. a: abc-19 rapid test results by eurOiMMun and roche elecsys assay 
titre, showing whether participant was asymptomatic, among 268 “known positives” (approach 1). b: abc-19 results by eurOiMMun and roche 
elecsys titre among all 2579 “unknown previous infection status” eDsab-HOMe stream a and b participants (ie, all study participants except 
cases confirmed by polymerase chain reaction) (approach 2). lines reflect roche threshold (1.0) and eurOiMMun rule-out (0.8) and rule-in (1.1) 
thresholds recommended by manufacturers. 0.8 threshold was used for eurOiMMun in this study
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between reader variation
With the AbC-19 device, many bands were weak 
visually; for example, among the 462 samples from 
streams A and B that tested positive with the Roche 
reference standard, consensus scoring found that 62 
(13%) had no visible band, 199 (43%) had a band 
scored 1, and 201 (44%) had a band scored 2. Expert 
readers differed in rating the device as positive or 
negative in 189/4842 (3.9%) devices, requiring a 
consensus decision (table S8). A log-linear regression 
model fitted to the known positives and known 
negatives estimated the sensitivity and specificity of an 
individual reader reading the device as 91.4% (95% 
credible interval 88.2% to 93.9%) and 97.6% (97.0% 
to 98.1%), respectively (supplementary material, table 
S8). These point estimates are lower than the estimates 
derived when using the consensus approach used in 
WHO evaluations with sensitivity and specificity of 
92.5% (88.8% to 95.1%) and 97.9% (97.2% to 98.4%) 
(table 1 and table 2).
Different test sensitivity in Pcr positive versus 
immunoassay positive samples
Among participants from streams A and B with 
immunoassay positive results, we investigated why 
AbC-19 test sensitivity in people who had not had 
a previous positive PCR test was less than in those 
who had had confirmation by PCR. As the AbC-19 
test detects anti-S antibody, we compared results 
with anti-S antibody indices obtained using the 
EUROIMMUN immunoassay. PCR positive participants 
had higher anti-S antibody titres (median 4.14 v 5.63 
units; P=0.001; fig 3, A). As the AbC-19 test band 
strength observed by the three observers increases, 
so too does the anti-S antibody index detected by 
EUROIMMUN immunoassays, showing that band 
strength is proportional to antibody concentrations 
(fig 3, B). Importantly, at low antibody concentrations, 
corresponding to EUROIMMUN indices of less than 
3, the AbC-19 test is insensitive (fig 4). However, 
such low concentrations are common: 84/263 (32%) 
participants who had previously been PCR positive had 
anti-S antibody indexes less than 3, compared with 
146/372 (39%) who had not but were seropositive 
(fig 3, A). In summary, compared with a less selected 
population, fewer PCR positive people had the low 
antibody concentrations at which the AbC-19 test is 
insensitive.
Positive and negative predictive values
Table 4 shows estimates of positive and negative 
predictive value. Given the different estimates of 
sensitivity noted above from approaches 1 and 2, 
we observed some differences across the two sets of 
estimates of positive and negative predictive value 
presented. We consider the approach 2 estimates to be 
most applicable to a potential target testing population 
of adult frontline workers seeking antibody testing, as 
we would expect people with PCR confirmation to be 
less likely to seek antibody testing.
Assuming a scenario of testing 1 million key 
workers with unknown previous infection status, of 
whom 10% had actually been previously infected, we 
estimate that approximately 84 700 true positive and 
table 3 | approach 2: abc-19 results on all eDsab-HOMe samples, compared with immunoassay reference standards
reference abc-19 positive abc-19 negative total Proportion, % (95% ci)
“Known positive” samples (n=268)
Roche Elecsys:
 Positive 244 15 259 Sensitivity of AbC-19: 94.2 (90.7 to 96.5)
 Negative 4 5 9 Agreement: 55.6 (26.7 to 81.1)
EUROIMMUN:
 Positive 240 10 250 Sensitivity of AbC-19: 96.0 (92.8 to 97.8)
 Negative 8 10 18 Agreement: 55.5 (33.7 to 75.4)
Composite reference standard:
 Positive 247 16 263 Sensitivity of AbC-19: 93.9 (90.3 to 96.2)
 Negative 1 4 5 Agreement: 80.0 (37.6 to 99.0)
Total 248 20 268 Proportion positive on AbC-19: 92.5 (88.8 to 95.1)
all “unknown previous infection status” samples (n=2579)
Adapted WHO classification:
 Suspected 168 228 396 42.4 (37.7 to 47.3)
 Early probable 12 133 145 8.3 (4.8 to 13.9)
 Uncertain 22 123 145 15.2 (10.2 to 21.9)
 No 122 1771 1893 6.4 (5.4 to 7.6)
Roche Elecsys:
 Positive 300 54 354 Sensitivity of AbC-19: 84.7 (80.6 to 88.1)
 Negative 24 2201 2225 Specificity of AbC-19: 98.9 (98.4 to 99.3)
EUROIMMUN:
 Positive 296 50 346 Sensitivity of AbC-19: 85.5 (81.5 to 88.9)
 Negative 28 2205 2233 Specificity of AbC-19: 98.7 (98.2 to 99.1)
Composite reference standard:
 Positive 303 69 372 Sensitivity of AbC-19: 81.5 (77.2 to 85.1)
 Negative 21 2186 2207 Specificity of AbC-19: 99.0 (98.5 to 99.4)
Total 324 2255 2579 Proportion positive on AbC-19: 12.6 (11.3 to 13.9)
Results are presented separately for “known positive” (WHO “confirmed” category: n=268) and “unknown previous infection status” (all other EDSAB-HOME participants: n=2579) samples. 
Composite reference standard was “positive on at least one of Roche Elecsys or EUROIMMUN versus negative on both.”
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18 900 false positive results would occur, meaning that 
approximately one in five positive test results would 
be false positive (positive predictive value of 81.7%, 
76.8% to 85.8%; table 4).
discussion
In a series of analyses involving two complementary 
and distinct cohorts, we made several observations 
relevant to the performance of emerging, scalable 
antibody tests for SARS-CoV-2. Firstly, on the basis 
of an analysis of pre-pandemic blood samples from 
almost 2000 blood donors in England, we estimated 
the specificity of the AbC-19 test to be 97.9% (95% 
confidence interval 97.2% to 98.4%). That is, 2.1% 
of people who did not have a previous SARS-CoV-2 
infection incorrectly tested positive. Next, we analysed 
samples from 2847 key workers in the UK. Among 
those who self-reported previous PCR positivity, we 
estimated the sensitivity of the AbC-19 test to be 92.5% 
(88.8% to 95.1%). In this group, participants with PCR 
confirmed covid-19 had symptom onset a median of 63 
(interquartile range 52-75) days before the sample was 
taken, which is sufficient for antibody development.2 17 
This group is not, however, a representative sample 
of all people who have been infected with SARS-
CoV-2: we would expect asymptomatic and lower 
severity cases to be under-represented, particularly 
given limited test availability in the early stage of 
the pandemic when many people became ill. We 
found evidence that this estimate of test sensitivity is 
upwardly biased, owing to lack of representativeness, 
by comparing AbC-19 test results with results on a 
sensitive immunoassay17 separately among those with 
previous PCR confirmation versus those with unknown 
previous infection status before antibody testing. 
Among the participants with PCR confirmed infection, 
comparison with this alternative reference standard 
produced a similar estimate of sensitivity (94.2%, 
90.7% to 96.5%).
By contrast, among EDSAB-HOME participants 
who did not know or were unsure of their previous 
infection status (that is, all participants who had not 
had a previous positive PCR test, a likely user group 
for the test), we estimated the sensitivity of the AbC-
19 test to be lower (84.7%, 80.6% to 88.1%) using 
the same immunoassay reference standard. This 
“spectrum bias”12 effect occurred because the PCR 
positive participants had, on average, higher antibody 
concentrations than other seropositive people. As 
people who have had SARS-CoV-2 previously confirmed 
by PCR would probably be less likely to seek antibody 
testing than other people, we consider this lower 
estimate (84.7%) to be a more appropriate estimate of 
test sensitivity for a potential use case in which people 
were to choose to take the test to find out their own 
previous infection status. For an alternative potential 
use of population serosurveillance,3 4 the estimate 
of test sensitivity of 86.6% (83.2% to 89.4%), which 
derives from an analysis of all EDSAB-HOME stream A 
and B participants, irrespective of PCR positivity, may 
be more appropriate. Finally, we observed that AbC-19 
test bands were often weak, a finding also reported in 
another laboratory based evaluation of AbC-19.16 In 
PCR status
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Fig 3 | relation between abc-19 test results and anti-s immunoassay indices. a: 
cumulative anti-s (eurOiMMun) antibody index, stratified by polymerase chain 
reaction (Pcr) status. b: abc-19 test band strength and its relation to anti-s 
(eurOiMMun) antibody index. test bands strength refers to sum of test band 
intensities (scored as 0, 1, or 2) by three observers. eia=enzyme immunoassay
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our study, discordant interpretation by highly trained 
laboratory technicians accounted for almost 4% of 
tests.
strengths and weaknesses of study
Key strengths of this study include precise estimation 
of test specificity owing to study of almost 2000 pre-
pandemic samples, and evaluation in a cohort of 
almost 2900 key workers consisting of people both with 
known and with unknown previous infection status, 
enabling study of potential spectrum bias. Our study 
also has potential limitations. Firstly, in common with 
all evaluations of SARS-CoV-2 antibody tests, a “gold 
standard” test to evaluate a new test against is lacking. 
In this study, we aimed to estimate sensitivity and 
specificity to detect previous SARS-CoV-2 infection. Our 
approach to estimating test specificity based on pre-
pandemic samples (collected in 2016-17) is therefore 
robust, as we can be confident that these samples were 
taken from people never infected with SARS-CoV-2. 
Unbiased estimation of test sensitivity for this target 
is, unfortunately, more difficult. We took presence of 
antibodies according to a sensitive immunoassay to 
be a proxy for previous infection.1 2 15 After infection, 
most, but not all, infected people seroconvert.12 
However, antibody concentrations decline over 
time.13 15 19 As our approach will necessarily miss 
any individuals without antibodies, we may have 
overestimated the sensitivity of the AbC-19 test to 
detect previous infection, particularly over a longer 
time period. Furthermore, results on the immunoassays 
we used as reference standards are themselves subject 
to some small degree of misclassification as to whether 
antibodies are present.
Secondly, we evaluated AbC-19 in a laboratory 
setting, using venous blood samples, rather than 
having participants do the test themselves using finger 
prick samples. Tests were read manually, as specified 
in the manufacturer’s instructions for use; we used 
a majority of three reads as the test result, which we 
have shown may overestimate test sensitivity by about 
1% compared with a single trained laboratory reader. 
The sensitivity and specificity of the test if used by 
untrained members of the general public at home 
may be lower still, a factor that would need further 
investigation if these tests were to be used by the 
general population.3 Thirdly, our cohort of key workers 
included few people aged over 65 years, suggesting the 
need for further evaluation of the assay at older ages 
when risk of covid-19 is substantially higher.
Finally, of the 354 participants with a positive 
Roche immunoassay result who had unknown 
previous infection status before antibody testing 
(the denominator for our estimate of 84.7% test 
sensitivity), 62% reported symptoms compatible with 
covid-19 since 1 January 2020. Although study eligi-
bility criteria did not depend on symptoms, people 
who believed that they had had covid-19 because 
of previous symptoms may have been more likely to 
volunteer. This could mean that our estimate of test 
sensitivity is upwardly biased.
comparison with other studies
Most previous evaluations of LFIAs have used a “two 
gate” design, in which tests are performed on two 
groups of samples: PCR positives and pre-pandemic 
sera.2 4 20-22 This study design remains an important 
tool in evaluating accuracy, owing to the lack of a 
gold standard test, as discussed above. However, we 
have shown that using only PCR confirmed cases can 
overestimate test sensitivity. Therefore, results from 
these previous studies may be optimistic and should be 
interpreted with caution. Notably, the PCR confirmed 
cases in our study were key workers, few of whom were 
LFIA test result, as per WHO algorithm
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1 2 3 4 5 6
Fig 4 | sensitivity of abc-19 test at varying levels of anti-s antibody index. lFia=lateral 
flow immunoassay
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admitted to hospital and a small minority of whom 
were asymptomatic. The extent of spectrum bias may 
be greater if sensitivity is estimated using only PCR 
positive hospital patients.
To our knowledge, only one previous evaluation 
of the AbC-19 test has been described in a medRxiv 
pre-print article that is yet to be peer reviewed.16 That 
previous study reported estimates of sensitivity and 
specificity of 97.7% (95.7% to 99.3%) and 100% 
(100% to 100%), respectively (notably the latter 
confidence interval, around an observed proportion of 
350/350, is reported more appropriately as 98.95% to 
100% on the manufacturer’s website23). Our estimates 
of both sensitivity and specificity are, therefore, lower 
than those from the earlier study. In a low prevalence 
setting, the difference in specificity would be especially 
important: for example, if 1 million people were tested, 
of whom 10% had been previously infected with SARS-
CoV-2, the previous study predicts no false positives 
using the AbC-19 test, whereas our study predicts 
18 900 false positives. The difference in results was 
probably driven by sample selection factors: Robertson 
et al estimated specificity by using only samples that 
were negative on three immunoassays.16 This means, 
for example, that any pre-pandemic samples that falsely 
tested positive using any of three immunoassays would 
be excluded. Similarly, sensitivity was estimated from 
only samples that were positive on EUROIMMUN and 
at least one other immunoassay. Exclusion of samples 
with unclear “true” antibody status can be expected 
to lead to overestimation of both test sensitivity and 
specificity.
Meaning of study: possible explanations and 
implications for clinicians and policy makers
For a population with 10% prevalence of previous 
infection, we estimated a positive predictive value of 
81.7% for the AbC-19 test. This means that about one 
in five positive AbC-19 tests would be a false positive. 
If the AbC-19 test were to be used for mass population 
screening in a relatively low prevalence setting, we 
would anticipate a large number of false positive 
results (for example, 18 900 for every 1 million tests 
carried out). Consequently, AbC-19 test positives 
would need to be checked with a confirmatory assay, 
a practice followed in HIV and syphilis serodiagnosis, 
if such an assay for SARS-CoV-2 could be shown to 
be sufficiently specific for this purpose. The false 
positive rate may be higher still if accuracy of the test 
is lower when deployed in the field than observed in 
our laboratory study. We also emphasise that our study 
does not answer the question of whether previous 
infection, or presence of antibodies, implies immunity, 
nor the duration of antibody or immune response. The 
alternative use of LFIAs for population surveillance 
requires statistical adjustments for imperfect sen-
sitivity and specificity.3 4 24 The precise adjustment, 
however, would depend on whether the objective 
was to estimate the proportion previously infected or 
simply the proportion with antibody. Considering the 
decline in antibody over time, the adjustment needed 
to estimate the proportion previously infected would 
be difficult to calculate. Finally, if people were to use 
and read the test themselves, rather than the test being 
read by trained laboratory technicians, or if a digital 
reader were developed, the accuracy of the test as read 
using these alternative approaches would need to be 
evaluated.
conclusions
In summary, we found evidence that the sensitivity 
of the AbC-19 test is lower among populations with 
unknown previous infection status than among PCR 
confirmed cases of SARS-CoV-2. This highlights the 
scope for overestimation of SARS-CoV-2 antibody 
test sensitivity in other studies, in which sensitivity 
has been estimated from only PCR confirmed cases. 
Assuming a prevalence of 10% for previous SARS-
CoV-2 infection, and that the performance observed 
in this laboratory study can be reproduced in field 
use, our findings suggest that around one in five key 
workers testing positive with the AbC-19 assay would 
be false positives.
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Prevalence of previous infection
5% 10% 15% 20% 25%
Positive predictive value
Based on sensitivity estimated from PCR confirmed cases* 69.8 (63.1 to 75.7) 83.0 (78.3 to 86.8) 88.6 (85.2 to 91.3) 91.6 (89.1 to 93.7) 93.6 (91.6 to 95.2)
Based on sensitivity estimated against Roche Elecsys  
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infection status†
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†Sensitivity 84.7% (80.6% to 88.1%), based on comparison with immunoassay reference standard in people with unknown true previous infection status (table 3).
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